BOSTON SCIENTIFIC CORP

Boston Scientific faces China’s new procurement rules, balancing quality and price in GI device bidding to stay competitive.

Boston Scientific’s $50.37 stock rebound shows robust growth, driven by its cutting‑edge medical device portfolio and strong 20.41 PE ratio.

Boston Scientific bolsters investor confidence with Wells Fargo conference talks, Q3 2026 financial call, and a director’s share surge, underscoring strong strategic direction in medical devices.

Boston Scientific’s stock slumps 60% yet shows a 3.6% rally and insider buying—discover how its $21 billion revenue growth and diversified medical devices could reshape investor sentiment.

Boston Scientific’s analyst sentiment shifts as TD Cowen cuts its target to $56.00 while the company trims jobs, sparking a mixed outlook on future growth.

Boston Scientific’s valuation tightens as analysts trim targets and the firm cuts jobs, raising concerns about its growth prospects and future innovation in medical devices.

Boston Scientific’s stock rebounds to $44.65 amid market volatility, showcasing its robust portfolio of minimally invasive devices and promising growth prospects for investors.

Boston Scientific tops Q1 earnings, beating EPS estimates but cuts 2026 sales guidance amid supply‑chain uncertainty—stock surges yet faces legal deadlines.

Boston Scientific shares hit a $61.86 close as investors face a May 4, 2026 litigation deadline—earnings guidance shows upside while institutional selling raises caution.

Boston Scientific’s CHAMPION‑AF trial hits all endpoints, boosting its $93B market cap. See how institutional trades, SEC filings, and device launches shape its growth.